Biotech Bros

This week on the podcast Agustin sits down with the Lynn Kirkpatrick the CEO of Ensysce Biosciences. Ensysce is an innovative company that is seeking to address the opioid crisis by leveraging advanced chemistry to prevent opioid abuse and ensure targeted and appropriate dosing of pain medications. Apart from opioids, Ensysce is looking to leverage their technology across a host of indications with the goal of making  drug delivery safer and more effective. 

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses some new developments in the Alzheimer's space with the FDA's recent CRL for Eli Lilly's beta amyloid antibody. He also shares his thoughts on Leap Therapeutics' acquisition of Flame Biosciences and what it means for future commercialization strategies 

Listen on: Apple Podcasts   Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses the excitement for 2023 in biotech investing and highlights some key tailwinds that could provide a return to positive returns for investors. He also discusses the rather lackluster JPM conference and highlights the troubles plaguing Fate Therapeutics and other natural killer cell therapy companies. 

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses Madrigal Pharmaceuticals' recent phase III win in NASH, he highlights another monoclonal antibody in the Alzheimer's space, and provides a reflection on the markets in 2022. 

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin shares some recent action and news in the biotech market from failed acquisitions to a pending purchase to questions around a synthetic biology powerhouse.

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin provides updates on key readouts from Affimed and Leap Therapeutics in particular setting the record straight for their recent data readouts. In addition he shares some exciting news regarding a new initiative!

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin talks about the recent fluctuations within the market, the 300 million dollar IPO of a big time base editing gene therapy company, and highlights an interesting play within the NASH space. 

Listen on: Apple Podcasts   Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin sits down with the Bryan Kobel CEO of TC Biopharm. Bryan spent years leading healthcare investment banking at EF Hutton and the Alberleen Group before switching roles and joining TC Biopharm. 

On this podcast we discuss a host of topics from TC Biopharm's IPO earlier in the year, to the state of biotech and equity markets, to the transformative technology behind TC Biopharm.  

Listen on: Apple Podcasts   Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin talks recent macroeconomic trends and their implications on the stock market and biotech specifically, highlights the positive phase 3 data for another Biogen Alzheimer's drug, and shares the recent approval for Amylyx Pharmaceuticals and their 6-figure a year drug for ALS. 

Listen on: Apple Podcasts   Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

This week on the podcast Agustin discusses news around Amgen's big 1L data drop for its KRAS inhibitor Lumakras, the shifting perceptions for $AMLX and what could become an approval for their ALS therapy, and the shortsightedness of the FDA and CDC around approving covid boosters based only on mouse data!

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com

Listen on: Apple Podcasts   Spotify

If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com